Results 201 to 210 of about 32,756 (253)

The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon‐Like Peptide‐1‐Based Therapies

Diabetes, Obesity and Metabolism, EarlyView.
Rune Viig Overgaard, Henrik Agersø, Christian Hollensen, Naveen Rathor, Eric M. Bomberg   +4 more
wiley   +1 more source

The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review. [PDF]

Cureus
Huang JXF, Wu J, Ahmad H, Li J, Joshi S, Yousaf A, Pemminati R, Pemminati S.   +7 more
europepmc   +1 more source

Perioperative risks of glucagon-like peptide-1 receptor agonists and their implications in airway management using supraglottic airway devices. [PDF]

Anesth Pain Med (Seoul)
Oh CS, Lee S, Hong B.
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes. [PDF]

Nat Med
Xu Y, Malek ND, Chang AR, Echouffo-Tcheugui JB, Selvin E, Grams ME, Fang M, Shin JI.   +7 more
europepmc   +1 more source

Perceptions, Attitudes and Barriers to Obesity Management in Pakistan: Country‐Specific Analysis From the ACTION‐APAC Study

Diabetes, Obesity and Metabolism, EarlyView.
Asma Ahmed, A. H. Aamir, Muslim Atiq, Mohammad Imtiaz Hasan, Zahid Miyan, Kashif Shafique, Atika Shaheer, Muhammad Aleem Zahir, Amber Hussain   +8 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-Like Peptide-1 Receptor Agonists

Surgical Clinics of North America
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
  +7 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Journal of Clinical Psychopharmacology
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire   +3 more sources